Ge Long Hui·2025-08-22 04:05Core Viewpoint - 康希诺生物 reported a significant improvement in its financial performance for the first half of 2025, with a revenue increase and a notable reduction in net loss [1] Financial Performance - The company achieved a revenue of 374 million yuan, representing a year-on-year growth of 31.1% [1] - The net loss attributable to shareholders was 13.485 million yuan, a substantial decrease from a net loss of 225 million yuan in the same period last year [1] Vaccine Sales and Profitability - Revenue from meningococcal vaccines increased by 38.4% due to the sales growth of MCV4 Menhycia [1] - The gross margin for vaccine products improved to 79.3%, up 12 percentage points year-on-year, benefiting from higher sales of high-margin vaccines and increased capacity utilization [1] Analyst Ratings and Forecasts - 美银证券 raised its earnings per share forecast for 康希诺生物 by 7%-11% for the years 2028 to 2034, citing the company's leading R&D capabilities across various technological routes and strong overseas expansion potential [1] - The target price for 康希诺生物 was increased from 43 HKD to 56 HKD, maintaining a "buy" rating [1]